Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Dade Behring to Develop Cardiac Marker Tests

By HospiMedica staff writers
Posted on 07 Dec 2004
Certain semi-exclusive diagnostic rights for the commercialization of automated diagnostic tests using myeloperoxidase (MPO) have been granted to Dade Behring (Deerfield, IL, USA) by The Cleveland Clinic (OH, USA).

According to research conducted at The Cleveland Clinic, MPO testing may be particularly beneficial in patients with chest pain who exhibit low initial troponin (a) levels, usually an indication that no heart muscle cells have died. More...
In this case, the presence of an elevated MPO level has been linked to risk for subsequent cardiac events. Therefore, a simple MPO blood test has the potential to help doctors identify patients at risk of subsequent heart attack and refer them for treatment prior to the occurrence of heart damage.

Researchers at the Cleveland Clinic investigated initial MPO levels in more than 600 patients in the emergency room complaining of chest pain. By using an MPO blood test in addition to laboratory-based risk assessments, they increased their ability to identify patients who would have heart problems during the next 30 days to six months from 54% to 85%. A larger study in Europe has confirmed these results.

"The potential of a simple blood test to help identify patients at particular risk of heart damage is very exciting,” commented Eric J. Topol, M.D., chairman of The Cleveland Clinic's department of cardiovascular medicine. "We need to build on the great success of the troponin test in changing medicine, and the MPO test may be a way to do that.”





Related Links:
Dade Behring
Cleveland Clinic

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.